Recent Press Releases

Alliance Foundation Trials and Austrian Breast & Colorectal Cancer Study Group Open Largest Global Phase 3 Trial of Targeted Therapy, IBRANCE® (palbociclib), for Patients with Hormone Receptor–Positive Early Breast Cancer

NEW YORK--(BUSINESS WIRE)--The Alliance Foundation Trials, LLC (AFT), the Austrian Breast & Colorectal Cancer Study Group (ABCSG) and Pfizer Inc. today announced the launch of the Palbociclib...

U.S. District Court Rules in Lilly's Favor on Alimta Vitamin Regimen Patent

U.S. District Court Rules in Lilly's Favor on Alimta Vitamin Regimen Patent INDIANAPOLIS, Aug. 25, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the U.S. District...

SUCAMPO LAUNCHES TENDER OFFER TO ACQUIRE R-TECH UENO

Acquisition Expected to be Immediately Accretive Advances Sucampo Strategy to Strengthen Financial Performance and Diversify Pipeline Acquisition Expected to Close in Q4 2015 Company to Host...

Mylan Comments on Misleading Statements Made by Perrigo

HERTFORDSHIRE, England and PITTSBURGH, Aug. 25, 2015 /PRNewswire/ -- Mylan N.V. (NASDAQ: MYL) today commented on the misleading statements made by Perrigo Company plc (NYSE: PRGO; TASE) in relation...

Shire to Attain Enhanced CINRYZE® Manufacturing Flexibility and Capacity

Shire to Attain Enhanced CINRYZE® Manufacturing Flexibility and Capacity The company enters into new agreement with Sanquin Lexington, Mass. – August 25, 2015 – Shire plc (LSE: SHP,...

Acorda Announces Patent Trials and Appeal Board (PTAB) Denies Both IPRs of AMPYRA Patents

ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics, Inc. (Nasdaq:ACOR ) today announced that the United States Patent and Trademark Office (USPTO) Patent Trials and Appeal Board (PTAB) will not...

Shire to Attain Enhanced CINRYZE® Manufacturing Flexibility and Capacity

Shire to Attain Enhanced CINRYZE® Manufacturing Flexibility and Capacity The company enters into new agreement with Sanquin Lexington, Mass. – August 25, 2015 – Shire plc (LSE: SHP,...

MSF STATEMENT ON RCEP TRADE NEGOTIATIONS IN KUALA LUMPUR

MSF STATEMENT ON RCEP TRADE NEGOTIATIONS IN KUALA LUMPUR AUGUST 24, 2015 — As the trade ministers of the 16 countries negotiating the Regional Comprehensive Economic Partnership (RCEP) meet in...

Allergan Issues Voluntary Nationwide Recall in the U.S. of Specific Lots of REFRESH® Lacri-Lube®, REFRESH P.M. ®, FML® (fluorometholone ophthalmic ointment) 0.1%, and Blephamide® (sulfacetamide sodium and prednisolone acetate ophthalmic ointment, USP) 10%

FOR IMMEDIATE RELEASE - DUBLIN, IRELAND – Aug. 24, 2015 – Allergan plc, today announced that it is conducting a voluntary recall down to consumer level of specific lots of its...

Expert committee BACKS Hospira's InflectraTM

Comparable, safety and efficacy of first mAb biosimilar therapy confirmed by TGA and PBAC Melbourne, Australia, Aug. 21, 2015 –The PBAC today recommended that InflectraTM (infliximab),1 the...

Depomed's Board of Directors Unanimously Rejects Revised Proposal from Horizon Pharma plc

Horizon's Proposal Has Current Value Below $30 Per Share, Which Is Less Than Prior Proposal NEWARK, Calif., Aug. 19, 2015 /PRNewswire/ -- Depomed, Inc. (NASDAQ: DEPO) ("Depomed" or the...

FDA's Big Mistake: Expect Flibanserin to Be Pulled From the Market in a Few Years

Statement of Dr. Sidney Wolfe, Founder and Senior Adviser, Public Citizen's Health Research Group Note: Dr. Sidney Wolfe, founder and senior adviser of Public Citizen's Health Research Group,...

Valeant Pharmaceuticals To Acquire Sprout Pharmaceuticals

Enters Sexual Health Market with FDA-Approved Addyi™ (flibanserin 100mg) Addyi Expected to Launch in U.S. in the Fourth Quarter of 2015 LAVAL, Quebec and RALEIGH, N.C., Aug. 20, 2015...

Jardiance® demonstrated cardiovascular (CV) risk reduction in people with type 2 diabetes at high risk for CV events

RIDGEFIELD, Conn and INDIANAPOLIS, Aug. 20, 2015 /PRNewswire/ -- Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced positive top-line results from EMPA-REG OUTCOME®. This...

Novartis drug Odomzo® gains EU approval for locally advanced basal cell carcinoma, providing new non-invasive therapy for patients

Approval follows positive CHMP opinion based on pivotal Phase II study showing durable objective response rate per central review of 56% in patients with laBCC[1] Basal cell carcinoma is the most...

Hospira's Inflectra™ registered in Australia

Melbourne, Australia, Aug 20, 2015 – Hospira today announced that Inflectra™ (infliximab), the first monoclonal antibody (mAb) biosimilar therapy, has been registered in Australia. This...

Horizon Pharma plc to Amend Preliminary Solicitation Statement to Include Proposed Nominees for Depomed's Board

Horizon Pharma plc to Amend Preliminary Solicitation Statement to Include Proposed Nominees for Depomed's Board Horizon Pharma Intends to Seek Election of Its Slate at Special Meeting; Horizon...

Cushman & Wakefield releases N.J. Pharma/Life Sciences Market Report

Cushman & Wakefield of New Jersey, Inc. One Meadowlands Plaza East Rutherford, New Jersey 07073 Media Contact: Evelyn Weiss Francisco: evelyn@caryl.com, (201) 796-7788...

Major restructuring to regain profitability and ensure value creation

Valby, Denmark, 2015-08-19 07:42 CEST (GLOBE NEWSWIRE) -- Lundbeck is initiating a restructuring programme which will reduce the total cost base by approximately DKK 3 billion with full effect in...

Seattle Genetics Announces FDA Regular Approval of ADCETRIS® (Brentuximab Vedotin) for Classical Hodgkin Lymphoma Patients at High Risk of Relapse or Progression as Post-Autologous Hematopoietic Stem Cell Transplantation Consolidation

-FDA Approval Based on the Phase 3 AETHERA Clinical Trial Results- -AETHERA Trial Also Converts Prior Accelerated Approval to Regular Approval in Treatment of Classical Hodgkin Lymphoma Patients who...